Fluconazole: Difference between revisions

(Replace manual dosing with dynamic SMW tables (Adult + Pediatric))
Line 5: Line 5:


==Adult Dosing==
==Adult Dosing==
===General===
===Indications by Disease===
[[Candidiasis]], oropharyngeal/esophageal
{{#ask: [[Has DrugName::Fluconazole]] [[Has Population::Adult]]
*100mg PO qday x 2 week to prevent relapse
|?Treats disease=Disease
 
|?Has Dose=Dose
[[Candida vaginitis]]
|?Has Context=Context
*Uncomplicated: 150mg PO x 1
|format=table
|limit=50
|mainlabel=-
|headers=show
|sort=Treats disease
}}


==Pediatric Dosing==
==Pediatric Dosing==
Candidiasis, oropharyngeal/esophageal:
===Indications by Disease===
*> 14 days old: 6mg/kg PO x 1, then 3mg/kg q24h x 7-14 days, max: 100mg/day
{{#ask: [[Has DrugName::Fluconazole]] [[Has Population::Pediatric]]
 
|?Treats disease=Disease
Tinea Capitis:
|?Has Dose=Dose
> 14 days old: 3-6mg/kg PO q24h x 6 weeks
|?Has Context=Context
|format=table
|limit=50
|mainlabel=-
|headers=show
|sort=Treats disease
}}


==Special Populations==
==Special Populations==

Revision as of 01:52, 20 March 2026

General

  • Type: Antifungal
  • Dosage Forms: IV; PO
  • Common Trade Names: Diflucan

Adult Dosing

Indications by Disease

DiseaseDoseContext
Acute necrotizing ulcerative gingivitis200mg PO daily x 14 daysImmunocompromised
Candida vulvovaginitis150mg PO oncePreferred; a second dose at 72hrs may be given if still symptomatic
Candida vulvovaginitis150mg PO q72h x 3 dosesSevere or immunosuppressed
Candida vulvovaginitis150mg PO qweek x 6 monthsRecurrent; long-term suppressive therapy
Cryptococcosis400mg PO/IV q24hrs x 6-12 monthsPulmonary not AIDS associated
Cryptococcosis400mg PO q24hrs x 6-12 monthsPulmonary with AIDS
Cryptococcosis400mg PO q24hrs x 8 weeksMeningitis consolidation not AIDS
Cryptococcosis400mg PO q24hrs x 8 weeksMeningitis consolidation with AIDS
Oropharyngeal candidiasis200 mg PO on day one, followed by 100 mg daily for two weeksAdult

Pediatric Dosing

Indications by Disease

DiseaseDoseContext
Cryptococcosis6-12mg/kg PO daily x 8 weeks (max 400mg)Pediatric Consolidation
Oropharyngeal candidiasis6 mg/kg PO on day one, followed by 3 mg/kg daily for two weeksPediatric
Tinea capitis6mg/kg PO daily (max 400mg) x 3-6 weeksSecond line

Special Populations

  • Pregnancy Rating: D
  • Lactation Risk Categories: safety unknown
  • Renal Dosing
    • Adult:CrCrl < 50, give usual loading dose x 1 then decrease dose 50%
    • Pediatric: CrCrl < 50, give usual loading dose x 1 then decrease dose 50%
  • Hepatic Dosing
    • Adult: not defined
    • Pediatric: not defined

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

  • hepatotoxicity
  • seizures
  • leukopenia
  • thrombocytopenia
  • anaphylaxis
  • steven-johnson syndrome
  • QT prolongation

Common

  • Nausea
  • Rash
  • Headache
  • vomiting
  • diarrhea
  • Transaminitis


Pharmacology

  • Half-life: 30 hour
  • Metabolism: Liver
  • Excretion: urine
  • Mechanism of Action: inhibits cytochrome P450 and sterol c-14 alpha-demethylation

See Also

==External Links]]